Pathophysiology of anorexia in the cancer cachexia syndrome

Journal of Cachexia, Sarcopenia and Muscle

Volumn 6, Issue 4, 2015, Pages 287-302

  Ezeoke, Chukwuemeka Charles ^a   Morley, John E ^b  

^a SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anorexia; Cancer cachexia syndrome; Loss of appetite; Pathophysiology

Indexed keywords

ADENOSINE PHOSPHATE; ADIPOCYTOKINE; ADIPONECTIN; CANNABINOID; COENZYME A; CYTOKINE; DYNAMIN; FATTY ACID; FATTY ACID SYNTHASE; GHRELIN; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 1; INTERLEUKIN 6; LACTIC ACID; MEGESTROL ACETATE; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE; NEUROTRANSMITTER; NITRIC OXIDE SYNTHASE; PARATHYROID HORMONE RELATED PROTEIN; PEPTIDE YY; PROOPIOMELANOCORTIN; PROSTAGLANDIN; SEROTONIN; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; ZINC;

ABDOMINAL CRAMP; ANOREXIA; BLEEDING; CACHEXIA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DEPRESSION; DYSPHAGIA; FEEDING; GLYCOLYSIS; HUMAN; HYPOXIA; ILEUS; INTERNALIZATION; LOSS OF APPETITE; MOUSE MODEL; MUCOSA INFLAMMATION; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ZINC DEFICIENCY; ZONA INCERTA;

EID: 84951560964     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12059     Document Type: Review

References (218)

1. Amitani M, Asakawa A, Amitani H, Inui A. Control of food intake and muscle wasting in cachexia. Int J Biochem Cell Biol 2013 Oct;45:2179–85.
2. Morley JE, Thomas DR, Wilson MM. Cachexia: Pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735–743.
3. Asakawa A, Fujimiya M, Niijima A, Fujino K, Kodama N, Sato Y, Kato I, Nanba H, Laviano A, Mequid MM, Inui A. Parathyroid hormone-related protein has an anorexigenic activity via activation of hypothalamic urocortins 2 and 3. Psychoneuroendocrinology 2010;35:1178–1186.
4. DeWys WD. Anorexia in cancer patients. Cancer Res 1977;37:2354–2358.
5. Imai H, Soeda H, Komine K, Otsuka K, Shibata H. Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer. BMC Palliat Care 2013;12:38.
6. Lloyd RB, Nemeroff CB. The role of corticotropin-releasing hormone in the pathophysiology of depression: Therapeutic implications. Curr Top Med Chem 2011;11:609–617.
7. Rosenthal MJ, Morley JE. Corticotropin releasing factor (CRF) and age-related differences in behavior of mice. Neurobiol Aging 1989;10:167–171.
8. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M, et al. IDO and interferon-alpha-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;10:538–544.
9. Myers JS. Proinflammatory cytokines and sickness behavior: Implications for depression and cancer-related symptoms. Oncol Nurs Forum 2008;35:802–807.
10. Fraga CAC, Sousa AA, Correa GTB, Jorge ASB, Jesus SF, Jones KM, et al. High hypoxia-inducible factor-1a expression genotype associated with Eastern Cooperative Oncology Group performance in head and neck squamous cell carcinoma. Head Neck Oncol 2012;4:77.
11. Sinno MH, Coquerel Q, Boukhettala N, Coeffier M, Gallas S, Terashi M, et al. Chemotherapy- induced anorexia is accompanied by activation of brain pathways signaling dehydration. Physiol Behav 2010;101:639–648.
12. López M, Lelliott CJ, Tovar S, Kimber W, Gallego R, Virtue S, et al. Tamoxifeninduced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes 2006;55:1327–1336.
13. Hornby P. Central neurocircuitry associated with emesis. Am J Med 2001;111:106S–112S.
14. Ramos EJB, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM. Cancer anorexia-cachexia syndrome: Cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004;7:427–434.
15. Noguchi Y, Yoshikawa T, Matsumoto A, Svaninger G, Gelin J. Are cytokines possible mediators of cancer cachexia? Surg Today 1996;26:467–475.
16. Matthys P, Billiau A. Cytokines and cachexia. Nutrition 1997;13:763–770.
17. Patra SK, Arora S. Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome. Clin Chim Acta 2012;413:1025–1034.
18. Inui A. Cytokines and sickness behavior: Implications from knockout animal models. Trends Immunol 2001;22:469–473.
19. Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides 1999;33:415–424.
20. Laviano A, Meguid MM, Yang ZJ, Gleason JR, Cangiano C, Rossi-Fanelli F. Crackign the riddle of cancer anorexia. Nutrition 1996;12:706–710.
21. Yang ZJ, Blaha V, Meguid MM, Laviano A, Oler A, Zadak Z. Interleukin-1alpha injection into ventromedial hypothalamic nucleus of normal rats depresses food intake and increases release of dopamine and serotonin. Pharmacol Biochem Behav 1999;62:61–65.
22. Banks WA, Farr SA, Morley JE. Entry of blood-borne cytokines into the central nervous system: Effects on cognitive processes. Neuroimmunomodulation 2002–2003;10: 319–327.
23. Martignoni ME, Kunze P, Friess H. Cancer cachexia. Mol Cancer 2003;2:36.
24. Bennani-Baiti N, Davis MP. Cytokines and cancer anorexia cachexia syndrome. Am J Hospice Pall Med 2008;25:407–411.
25. Uehara A, Sekiya C, Takasugi Y, Namiki M, Arimura A. Anorexia induced by interleukin 1: Involvement of corticotropin-releasing factor. Am J Physiol 1989;257:R613–R617.
26. Strassmann G, Jacob CO, Evans R, Beal D, Fong M. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6- mediated cancer cachexia. J Immunol 1992;148:3674–3678.
27. Lira FS, Yamashita AS, Rosa JC, Tavares FL, Caperuto E, Carnevali LC Jr., et al. Blockade of cytokine induced conditioned taste aversion by subdiaphragmatic vagotomy: Further evidence for vagal mediation of immune-brain communication. Neurosci Lett 1995;185:163–166.
28. Torelli GF, Meguid MM, Moldawer LL, Edwards CK 3rd, Kim HJ, Carter JL, et al. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol Regul Integr Comp Physiol 1999;277:R830–R855.
29. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol 1993;47:169–176.
30. Goehler LE, Busch CR, Tartaglia N, Relton J, Sisk D, Maier SF, et al. Blockade of cytokine induced conditioned taste aversion by subdiaphragmatic vagotomy: Further evidence of vagal mediation of immunebrain communication. Neurosci Lett 1995;185:163–166.
31. Jatoi A, Qi Y, Kendall G, Jiang R, McNallan S, Cunningham J, et al. The cancer anorexia/weight loss syndrome: Exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer. Support Care Cancer 2010;18:1299–1304.
32. Plata-Salaman CR. Interferons and central regulation of feeding. Am J Physiol 1992;263:R1222–R1227.
33. Matthys P, Heremans H, Opdenakker G, Billiau A. Anti-interferon-gamma antibody treatment, growth of Lewis lung tumors in mice and tumor-associated cachexia. Eur J Cancer 1991;27:182–187.
34. Gadek-Michalska A, Tadeusz J, Rachwalska P, Spyrka J, Bugajski J. Brain nitric oxide synthases in the interleukin-1β-induced activation of hypothalamicpituitary-adrenal axis. Pharmacol Rep 2012;64:1455–1465.
35. Ntikoudi E, Kiagia M, Boura P, Syrigos KN. Hormones of adipose tissue and their biologic role in lung cancer. Cancer Treat Rev 2014;40:22–30.
36. Shackelford RE, Mayhall K, Maxwell NM, Kandil E, Coppola D. Nicotinamide Phosphoribosyltransferase in Malignanacy: A review. Genes Cancer 2013;4:447–456.
37. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006;91:1578–1581.
38. Hufton SE, Moerkerk PT, Brandwijk R, de Bruïne AP, Arends JW, Hoogenboom HR. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 1999;463:771–82.
39. Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007;130:1095–1107.
40. Patel ST, Mistry T, Brown JE, Digby JE, Adya R, Desai KM, et al. A novel role for the adipokine visfatin/pre-B cell colonyenhancing factor 1 in prostate carcinogenesis. Peptides 2010;31:51–57.
41. Park BS, Jin SH, Park JJ, Park JW, Namgoong IS, Kim YI, et al. Visfatin induces sickness responses in the brain. PLoS One 2011;6e15981:.
42. Goldman RD, Kaplan NO, Hall TC. Lactic dehydrogenase in human neoplastic tissues. Cancer Res 1964;24:389–399.
43. Warburg O. On the origin of cancer cells. Science 1956;123:309–314.
44. Crispens CG. Serum lactic dehydrogenase levels in mice during the devlepment of autochthonous and chemically induced tumors. J Natl Cancer Inst 1963;30:361–366.
45. Hsieh KM, Mao SS, Sasamanonth K. Serum lactic dehydrogenase activity after excision of transplanted tumors. Cancer Res 1959;19:700–704.
46. Wenner CE, Spirtes MA, Weinhouse S. Metabolism of neoplastic tissue. II. A survey of enzymes of the citric acid cycle in transplanted tumors. Cancer Res 1952;12:44–49.
47. Bierman HR, Hill BR, Reinhardt L, Emory E. Correlation of serum lactic dehydrogenase activity with the clinical status of patients with cancer, lymphomas, and the leukemias. Cancer Res 1957;17:660–667.
48. Hill JH. Serum lactic dehydrogenase in cancer patients. JNatl Cancer Inst 1957;18:307–313.
49. White LP. Serum enzymes. II. Glycolytic enzymes in patientswith cancer and other diseases. J Natl Cancer Inst 1958;21:671–684.
50. Brindley CO, Francis FL. Serum lactic dehydrogenase and glutamic-oxaloacetic transaminase correlations with measurements of tumor masses during therapy. Cancer Res 1963;23:112–117.
51. Michaelson MD, Stadler WM. Predictive markers in advanced renal cell carcinoma. Sermin Oncol 2013;40:459–464.
52. Bales CA, Mayer J. Depression of feed intake of goats by metabolites injected during meals. Am J Physiol 1969;217:1830–1836.
53. Baile CA, Zinn WM, Mayer J. Effects of lactate and other metabolites on food intake of monkeys. Am J Physiol 1970;219:1606–1613.
54. Silberbauer CJ, Surina-Baumgartner DM, Arnold M, Langhans W. Prandial lactate infusion inhibits spontaneous feeding in rats. Am J Physiol Regul Integr Comp Physiol 2000;278:R646–R653.
55. Guillod-Maximin E, Lorsignol A, Alquier T, Pénicaud L. Acute Intracarotid glucose injection towards the brain induces specific c-fos activation in hypothalamic nuclei: Involvement of astrocytes in cerebral glucose-sensing in rats. J Neuroendocrinol 2004;16:464–471.
56. Borg MA, Tamborlane WV, Shulman GI, Sherwin RS. Local lactate perfusion of the ventromedial hypothalamus suppresses hypoglycemic counter-regulation. Diabetes 2003;52:663–666.
57. Kokorovic A, Cheung GW, Rossetti L, Lam TK. Hypothalamic sensing of circulating lactate regulates glucose production. J Cell Mol Med 2009;13:4403–4408.
58. Lam CK, Chari M, Lam TK. CNS regulation of glucose lomeostasis. Physiology (Bethesda) 2009;24:159–170.
59. Lam CK, Chari M, Wang PY, Lam TK. Central lactate metabolism regulates food intake. Am J PHysiol Endocrionl Metab 2008;295:E491–496.
60. Cortes-Campos C, Elizondo R, Carril C, Martinez F, Boric K, Nualart F, et al. MCT2 expression and lactate influx in anorexigenic and orexigenic neurons of the arcuate nucleus. PLoS One 2013;8:e62532.
61. Schultes B, Schmid SM, Wilms B, Jauch-Chara K, Oltmanns KM, Hallschmid M. Lactate infusion during euglycemia but not hypoglycemia reduces subsequent food intake in healthy men. Appetite 2012;58:818–821.
62. Zheng ZH, Sederholm F, Anderstam B, Qureshi AR, Wang T, Sodersten P, et al. Acute effects of periotoneal dialysis solutions on appetite in non-uremic rats. Kidney Int 2001;60:2392–2398.
63. Zheng ZH, Anderstam B, Yu X, Qureshi AR, Hiemburger O, Lindholm B, et al. Bicarbonate-based periotoneal dialysis solution has less effect on ingestive behavior than lactate-based peritoneal dialysis solution. Perit Dial Int 2009;29:656–663.
64. Cassolla P, Moreira CC, Liboni TF, Yu X, Zaia CT, Borba-Murad GR, Bazotte RB, et al. Changes in blood metabolic parameters during the development of Walker-256 tumour-induced cachexia in rats are not caused by decreased food intake. Cell Biochem Funct 2012;30:265–270.
65. Chance WT, Dayal R, Friend LA, James JH. Elevated blood lactate is not a primary cause of anorexia in tumor-bearing rats. Nutr Cancer 2004;48:174–181.
66. Cha SH, Lane MD. Central lactate metabolism suppresses food intake via the hypothalamic AMP kinase/malonyl-CoA signaling pathway. Biochem Biophys Res Communic 2009;386:212–216.
67. Morley JE. The neuroendocrine control of appetite: The role of the endogenous opiates, cholecystokinin, TRH, gammaamino-butyric-acid and the diazepam receptor. Life Sci 1980;27:355–368.
68. Morley JE, Levein AS, Grace M, Kneip J. Dynorphin-(1–13), dopamine and feeding in rats. Pharmacol Biochem Behav 1982;16:701–705.
69. Krause R, James JH, Ziparo V, Fischer JE. Brain tryptophan and the neoplastic anorexia-cachexia syndrome. Cancer 1979;44:1003–1008.
70. Rossi Fanelli F, Cangiano C, Ceci F, Cellerino R, Franchi F, Menichetti ET, et al. Plasma tryptophan and anorexia in human cancer. Eur J Cancer Clin Oncol 1986;22:89–95.
71. Cangiano C, Cascino A, Ceci F, Laviano A, Mulieri M, Muscaritoli M, et al. Plasma and CSF tryptophan in cancer anorexia. J Neural Transm Gen Sect 1990;81:225–233.
72. Cangiano C, Testa U, Muscaritoli M, Meguid MM, Mulieri M, Laviano A, et al. Cytokines, tryptophan and anorexia in cancer patients before and after surgical tumor ablation. Anticancer Res 1994;14:1451–1456.
73. Cangiano C, Laviano A, Meguid MM, Mulieri M, Conversano L, Preziosa I, et al. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst 1996;88:550–552.
74. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002;7:468–473.
75. Kardinal CG, Loprinzi CL, Schaid DJ, Hass AC, Dose AM, Achmann LM, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657–2662.
76. Chance WT, von Meyenfeldt MF, Fischer JE. Changes in brain amines associated with cancer anorexia. Neurosci Biobehav Rev 1983;7:471–479.
77. Chance WT, Von Meyenfeldt M, Fischer JE. Delay of cancer anorexia following intraventricular injection of parachlorophenylalanine. Pharmacol Biochem Behav 1982;17:1043–1048.
78. Chance WT, von Meyenfeldt M, Fischer JE. Serotonin depletion by 5,7-dihydroxytryptamine or parachloroamphetamine does not affect cancer anorexia. Pharmacol Biochem Behav 1983;18:115–121.
79. Wang W, Danielsson A, Svanberg E, Lundholm K. Lack of effects by tricyclic antidepressant and serotonin inhibitors on anorexia in MCG 101 tumor-bearing mice with eicosanoid-related cachexia. Nutrition 2003;19:47–53.
80. Laviano A, Gleason JR, Meguid MM, Yang ZJ, Cangiano C, Rossi FF. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Investig Med 2000;48:40–48.
81. Chance WT, Cao L, Nelson JL, Foley-Nelson T, Fischer JE. Reversal of neurochemical aberrations after tumor resection in rats. Am J Surg 1988;155:124–130.
82. Blaha V, Yang ZJ, Meguid MM, Chai JK, Oler A, Zadak Z. Ventromedial nucleus of hypothalamus is related to the development of cancer-induced anorexia: In vivo microdialysis study. Acta Medica (Hradec Kralove) 1998;41:3–11.
83. Makarenko IG, Meguid MM, Gatto L, Chen C, Ramos EJ, Goncalves CG, Ugrumov MV. Normalization of hypothalamic serotonin (5-HT 1B) receptor and NPY in cancer anorexia after tumor resection: An immunocytochemical study. Neurosci Lett 2005;383:322–327.
84. Makarenko IG, Meguid MM, Gatto L, Goncalves CG, Ramos EJ, Chen C, et al. Hypothalamic 5-HT1B-receptor changes in anorectic tumor bearing rats. Neurosci Lett 2005;376:71–75.
85. Meguid MM, Ramos EJ, Laviano A, Varma M, Sato T, Chen C, et al. Tumor anorexia: Effects on neuropeptide Y and monoamines in paraventricular nucleus. Peptides 2004;25:261–266.
86. Edelman MJ, Gandara DR, Meyers FJ, Ishii R, O’Mahony M, Uhrich M, et al. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer 1999;86:684–688.
87. Feng F, Zhang P, He Y, Li Y, Zhou M, Chen G, Li L. Clinical comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea and anorexia. Chin Med Sci J 2002;17:168–172.
88. Sato T, Fetissov SO, Meguid MM, Miyata G, Chen C. Intra-supraoptic nucleus supiride improves anorexia in tumor-bearing rats. Neuroreport 2001;12:2429–2432.
89. Meguid MM, Fetissov SO, Varma M, Sato T, Zhang L, Laviano A, et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000;16:843–857.
90. Sato T, Meguid MM, Fetissov SO, Chen C, Zhang L. Hypothalamic dopaminergic receptor expressions in anorexia of tumorbearing rats. Am J Physiol Regul Integr Comp Physiol 2001;281:R1907–R1916.
91. Nichols MB, Maickel RP, Yim GK. Brain catecholamine alterations accompanying development of anorexia in rats bearing the Walker 256 carcinoma. Life Sci 1985;36:2223–2231.
92. Dasgupta PS, Lahiri T. Alteration of brain catecholamines during growth of benzo (a)pyrene induced murine fibrosarcoma. Neoplasma 1992;39:163–165.
93. Chuluyan HE, Wolcott RM, Chervenak R, Dunn AJ. Catecholamine, indoleamine and corticosteroid responses in mice bearing tumors. Neuroimmunomodulation 2000;8:107–113.
94. Chance WT, van Lammeren FM, Fischer JE. Feeding elicited by cholinergic and adrenergic hypyothalamic stimulation of anorectic tumor-bearing rats. Pharmacol Biochem Behav 1988;31:209–213.
95. Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008;18:158–168.
96. Morley JE, Flood JF, Horowitz M, Morley PMK, Walter MJ. Modulation of food-intake by peripherally administered amylin. Am J Physiology 1994;267:R178–R184.
97. MacIntosh CG, Morley JE, Wishart J, Morris H, Jansen JBMJ, Horowitz M, et al. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: Evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab 2001;86:5830–5837.
98. Silver AJ, Flood JF, Song AM, Morley JE. Evidence for a physiological role for CCK in the regulation of food intake in mice. Am J Physiol 1989;256:R646–R652.
99. Soenen S, Chapman IM. Body weight, anorexia, and undernutrition in older people. J Am Med Dir Assoc 2013;14:642–648.
100. Morley JE, Levine AS. Bombesin inhibits stress induced eating. Pharm Biochem Behav 1981;14:149–152.
101. Ku SK, Lee HS, Byun JS, Seo BI, Lee JH. Changes of the gastric endocrine cells in the C57BL/6 mouse after implantation of murine lung carcinoma: An immunohistochemical quantitative study. World J Gastroenterol 2005;11:1317–1323.
102. Jatoi A, Loprinzi CL, Sloan JA, Klee GG, Windschitl HE. Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: A North Central Cancer Treatment Group exploratory investigation. Cancer 2001;92:629–633.
103. Aalto Y, Forsgren S, Kjorell U, Funegard U, Franzen L, Henriksson R. Does bombesinlike peptide mediate radiation-induced anorexia and satiety? Acta Oncol 1999;38:1099–1102.
104. Morley JE, Flood JF. An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice. Life Sci 1987;41:2157–2165.
105. Moschovi M, Trimis G, Vounatsou M, Katsibardi K, Margeli A, Dimitriadi F, et al. Serial plasma concentrations of PYY and ghrelin during chemotherapy in children ith acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008;30:733–737.
106. Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005;90:2920–2926.
107. Flood JF, Morley JE. Increased food intake by neuropeptide Y is due to an increased motivation to eat. Peptides 1991;12:1329–1332.
108. McCarthy HD, McKibbin PE, Perkins AV, Linton EA, Williams G. Alterations in hypothalamic NPY and CRF in anorexic tumorbearing rats. Am J Physiol 1993;264: E638–E643.
109. Chance WT, Sheriff S, Zhang F, Kalmonpunpour M, Fischer JE, Balasubramaniam A. Reduction of plasma and hypothalamic neuropeptide Y in anorectic tumor-bearing rats. Proc Soc Neurosci 1990;16:774.
110. Chance WT, Sheriff S, Kasckow JW, Regmi A, Balasubramaniam A. NPY messenger RNA is increased in medial hypothalamus of anorectic tumor-bearing rats. Regul Pept 1998;75–76:347–353.
111. Nara-ashizawa N, Tsukada T, Maruyama K, Akiyama Y, Kajimura N, Nagasaki K, et al. Hypothalamic appetite-regulating neuropeptide mRNA levels in cachectic nude mice bearing human tumor cells. Metabolism 2001;50:1213–1219.
112. Nara-ashizawa N, Tsukada T, Maruyama K, Akiyama Y, Kajimura N, Yamaguchi K. Response of hypothalamic NPY mRNAs to a negative energy balance is less sensitive in cachectic mice bearing human tumor cells. Nutr Cancer 2001;41:111–118.
113. Bing C, Taylor S, Tisdale MJ, Williams G. Cachexia in MAC16 adenocarcinoma: Suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem 2001;79:1004–1012.
114. Makarenko IG, Meguid MM, Gatto L, Chen C, Ugrumov MV. Decreased NPY innervation of the hypothalamic nuclei in rats with cancer anorexia. Brain Res 2003;961:100–108.
115. Chance WT, Balasubramaniam A, Dayal R, Brown J, Fischer JE. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. Life Sci 1994;54:1869–1874.
116. Chance WT, Balasubramaniam A, Thompson H, Mohapatra B, Ramo J, Fischer JE. Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Peptides 1996;17:797–801.
117. Chance WT, Xiao C, Dayal R, Sheriff S. Alteration of NPY and Y1 receptor in dorsomedial and ventromedial areas of hypothalamus in anorectic tumorbearing rats. Peptides 2007;28:295–301.
118. Laviano A, Inui A, Meguid MM, Molfino A, Conte C, Rossi FF. NPY and brain monoamines in the pathogenesis of cancer anorexia. Nutrition 2008;24:802–805.
119. Morley JE, Flood JF. Competitive antagonism of nitric-oxide synthetase causes weight-loss in mice. Life Sci 1992;51:1285–1289.
120. Farr SA, Banks WA, Kumar VB, Morley JE. Orexin-A-induced feeding is dependent on nitric oxide. Peptides 2005;26:759–765.
121. Gaskin FS, Farr SA, Banks WA, Kumar VB, Morley JE. Ghrelin-induced feeding is dependent on nitric oxide. Peptides 2003;24:913–918.
122. Morley JE, Farr SA, Sell RL, Hileman SM, Banks WA. Nitric oxide is a central component in neuropeptide regulation of appetite. Peptides 2011;32:776–780.
123. Morley JE, Alshaher MM, Farr SA, Flood JF, Kumar VB. Leptin and neuropeptide Y (NPY) modulate nitric oxide synthase: Further evidence for a role of nitric oxide in feeding. Peptides 1999;20:595–600.
124. Wang W, Svanberg E, Delbro D, Lundholm K. NOS isoenzyme content in brain nickel as related to food intake in experimental cancer cachexia. Brain Res Mol Brain Res 2005;134:205–214.
125. Kola B. Role of AMP-activated protein kinase in the control of appetite. J Neuroendocrinol 2008;20:942–951.
126. Pimentel GD, Ropelle ER, Rocha GZ, Carvalheira JB. The role of neuronal AMPK as a mediator of nutritional regulation of food intake and energy homeostasis. Metabolism 2013;62:171–178.
127. Ropelle ER, Pauli JR, Zecchin KG, Ueno M, de Souza CT, Morari J, et al. A central role for neuronal adenosine 5’- monophosphate-activated protein kinase in cancer-induced anorexia. Endocrinology 2007;148:5220–5229.
128. Millington GW. The role of proopiomelanocortin (POMC) neurons in feeding behavior. Nutr Metab (Lond) 2007;4:18.
129. Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, et al. Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem 2008;16:5606–5618.
130. Tsujii S, Bray GA. Acetylation alters the feeding response to MSH and beta-endorphin. Brain Res Bull 1989;23:165–169.
131. Scarlett JM, Jobst EE, Enriori PJ, Bowe DD, Batra AK, Grant WF, et al. Regulation of central melanocortin signaling by interleukin-1(beta). Endocrniology 2007;148:4217–4225.
132. Grossberg AJ, Scarlett JM, Zhu X, Bowe DD, Batra AK, Braun TP, et al. Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130. Endocrinology 2010;151:606–616.
133. DeBoer MD. Update on melanocortin interventions for cachexia: Progress toward clinical application. Nutrition 2010;26:146.
134. Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res 2001;61:1432–1438.
135. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001;142:3292–3301.
136. Tran JA, Jiang W, Tucci FC, Fleck BA, Wen J, Sai Y, et al. Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor. J Med Chem 2007;50:6356–6366.
137. Jiang W, Tucci FC, Tran JA, Fleck BA, Wen J, Markison S, et al. Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2007;17:5610–5613.
138. Markison S, Foster AC, Chen C, Brookhart GB, Hesse A, Hoare SR, et al. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 2005;246:2766–2773.
139. Dallmann R, Weyermann P, Anklin C, Boroff M, Bray-French K, Cardel B, et al. The orally active melanocortin-4 receptor antagonist BL-6020/979: A promising candidate for the treatment of cancer cachexia. J Cachexia Sarcopenia Muscle 2011;2:163–174.
140. Weyermann P, Dallmann R, Magyar J, Anklin C, Hufschmid M, Dubach-Powell J, et al. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia inmice. PLoS One 2009;4e4774:.
141. Chance WT, Sheriff S, Sayal R, Balasubramaniam A. Refractor hypothalamic alpha-mSH satiety and AGRP feeding systems in rats bearing MCA sarcomas. Peptides 2003;24:1909–1919.
142. Pourtau L, Leemburg S, Roux P, Leste-Lasserre T, Costaglioli P, Garbay B, et al. Hormonal, hypothalamic and striatal responses to reduced body weight gain are attenuated in anorectic rats bearing small tumors. Brain Behav Immun 2011;25:777–786.
143. Suzuki H, Hashimoto H, Kawasaki M, Watanabe M, Otsubo H, Ishikura T, et al. Similar changes of hypothalamic feedingregulating peptides mRNAs and plasma leptin levels in PTHrP-, LIF-secreting tumors-induced cachectic rats and adjuvant arthritic rats. Int J Cancer 2011;128:2215–2223.
144. Hashimoto H, Azuma Y, Kawasaki M, Fujihara H, Onuma E, Yamada-Okabe H, et al. Parathyroid hormone-related protein induces cachectic syndromes without directly modulating the expression of hypothalamic feeding-regulating peptides. Clin Cancer Res 2007;13: 292–298.
145. Dwarkasing JT, van Dijk M, Dijk JF, Bookschoten MV, Faher J, Argiles JM, et al. Hypothalamic food intake regulation in a cancer-cachectic mouse model. J Cachexia Sarcopenia Muscle 2014;5:159–169.
146. Ihnatko R, Post C, Blomqvist A. Proteomic profiling of the hypothalamus in a mouse model of cancer-induced anorexiacachexia. Brit J Cancer 2013;109:1867–1875.
147. Shinyama H, Masuzaki H, Fang H, Flier JS. Regulation of melanocortin-4 receptor signaling agonist mediated desensitization and internalization. Endocrinology 2003;144:1301–1314.
148. Levine AS, Morley JE. The effect of prostaglandins (PGE2 and PGF2 alpha) on food intake in rats. Pharmacol Biochem Behav 1981;15:735–738.
149. Ruud J, Nilsson A, Engstrom Ruud L, Wang W, Nilsberth C, Iresio BM, et al. Cancerinduced anorexia in tumor-bearing mice is dependent on cyclooxygenase-1. Brain Behav Immun 2013;29:124–135.
150. Ohinata K, Suetsugu K, Fujiwara Y, Yoshikawa M. Activation of prostaglandin E receptor EP4 subtype suppresses food intake in mice. Protag Oth Lipid M 2006;81:31–36.
151. Desai S, Ashby B. Agonist-induced internalization and mitogen-activated protein kinase activation of the human prostaglandin EP4 receptor. FEBS Lett 2001;501:156–160.
152. Hadjimarkou MM, Silva RM, Rossi GC, Pasternak GW, Bodnar RJ. Feeding induced by food deprivation is differentially reduced by G-protein α-subunit antisense probes in rats. Brain Res 2002;955:45–54.
153. Carr KD, Tsimberg Y, Berman Y, Yamamoto N. Evidence of increased dopamine receptor signaling in food-restricted rats.
154. Milbury PE, Richer AC. Understanding the Antioxidant controversy: Scrutinizing the ‘fountain of youth’. Santa Barbara, CA: Greenwood Publishing Group; 2006. p.9.
155. Aydemir TB, Blanchard RK, Cousins RJ. Zinc supplementation of young men alters metallothionein, zinc transporter, and cytokine gene expression in leukocyte populations. Proc Natl Acad Sci U S A 2006;103:1699–1704.
156. Valko M, Morris H, Cronin MTD. Metals, toxicity and oxidative stress. Curr Med Chem 2005;12:1161–1208.
157. Nakashima AS, Dyck RH. Zinc and cortical plasticity. Brain Res Rev 2009;59:347–373.
158. Hambidge KM. Krebs NF. Zinc deficiency: A special challenge J Nutr 2007;137:1101.
159. Siren PM, Siren MJ. Systemic zinc redistribution and dyshomeostasis in cancer cachexia. J Cachexia Sarcopenia Muscle 2010;1:23–33.
160. Westin T, Ahlan E, Johansson E, Sandström B, Karlberg I, Edström S. Circulating levels of selenium and zinc in relation to nutritional status in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1989;115:1079–1082.
161. Gaetke LM, McClain CJ, Talwalkar RT, Shedlofsky SI. Effects of endotoxin on zinc metabolism in human volunteers. Am J Physiol 1997;272:E953–E956.
162. Allen JI, Bell E, Boosalis MG, Oken MM, McClain CJ, Levine AS, et al. Association between urinary zinc excretion and lymphocyte dysfunction in patients with lung cancer. Am J Med 1985;79:209–215.
163. Lindsey AM, Piper BF. Anorexia, serum zinc, and immunologic response in small cell lung cancer patients receiving chemotherapy and prophylactic cranial radiotherapy. J Nutr Cancer 1986.
164. Essatara MB, Levine AS, Morley JE, McClain CJ. Zinc deficiency and anorexia in rats: Normal feeding patterns and stress induced feeding. Physiol Behav 1984;32:469–474.
165. Yagi T, Asakawa A, Ueda H, Ikeda S, Miyawaki S, Inui A. The role of zinc in the treatment of taste disorders. Recent Pat Food Nutr Agric 2013;5:44–51.
166. Essatara MB, McClain CJ, Levine AS, Morley JE. Zinc deficiency and anorexia in rats: The effect of central administration of norepinephrine, muscimol and bromerogocryptine. Physiol Behav 1984;32:479–482.
167. Essatara MB, Morley JE, Levine AS, Elson MK, Shafer RB, McClain CJ. The role of the endogenous opiates in zinc deficiency anorexia. Physiol Behav 1984;32:475–478.
168. Suzuki H, Asakawa A, Li JB, Tsai M, Amitani H, Ohinata K, et al. Zinc as an appetite stimulator – the possible role of zinc in the progression of diseases such as cachexia and sarcopenia. Recent Pat Food Nutr Agric 2011;3:226–231.
169. Williamson PS, Browning JD, MacDonald RS. Megestrol acetate increases shortterm food intake in zinc-deficient rats. Physiol Behav 2002;75:323–330.
170. McCarthy MD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food intake in the rat: Effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994;265:99–102.
171. Leibowitz SF. Gonadal steroids and hypothalamic galanin and Neuropeptide Y: Role in eating behavior and body weight control in female rats. Endocrinology 1998;139:1771–1780.
172. White BD, Dean RG, Edwards GL, Martin RJ. Type II corticosteroid receptor stimulation increases NPY gene expression in basomedial hypothalamus of rats. Am J Physiol 1994;266:R1523–R1529.
173. Mantovani G, Maccio A, Lai P, Massa E, Ghiani M, Santona MC. Cytokine involvement in cancer anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate on cytokine down regulation and improvement of clinical symptoms. Crit Rev Oncog 1998;9:99–106.
174. Montovani G, Macciò A, Bianchi A, Curreli L, Ghiani M, Santona MC, et al. Megestrol acetate in neoplastic anorexia/cachexia: Clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 1995;25:135–141.
175. Jatoi A, Yamashita J, Sloan JA, Novotny PJ, Windschitl HE, Loprinzi CL. Dose megestrol acetate down-regulate interleukin-6 in patients with cancerassociated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer 2002;10:71–75.
176. Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013 March 28;3CD004310:.
177. Cuvelier GD, Baker TJ, Peddie EF, Casey LM, Lambert PJ, Distefano DS, et al. A randomized, double-blind, placebocontrolled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy. Pediatr Blood Cancer 2014;61:672–679.
178. Greig CA, Johns N, Gray C, Macdonald A, Stephens NA, Skipworth RJ, et al. Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy. Support Care Cancer 2014;22:1269–1275.
179. Kanat O, Cubukcu E, Avci N, Budak F, Ercan I, Canhoroz M, et al. Comparison of three different treatment modalities in the management of cancer cachexia. Tumori 2013;99:229–233.
180. Macciò A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: Evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 2012;124:417–425.
181. Madeddu C, Dessi M, Panzone F, Serpe R, Antoni G, Cau MC, et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib + megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr 2012;31:176–182.
182. Wen HS, Li X, Cao YZ, Zhang CC, Yang F, Shi YM, et al. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. Chemotherapy 2012;58:461–467.
183. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: A randomized trial. Support Care Cancer 2010;18:951–956.
184. Capasso R, Izzo AA. Gastrointestinal regulation of food intake: General aspects and focus on anandamide and oleoylethanolamide. J Neuroendocrinol 2008;20:39–46.
185. Deschamps B, Musaji N, Gillespie JA. Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. Int J Nanomedicine 2009;4:185–192.
186. Anonymous. Megestrol acetate NCD oral suspension—Par Pharmaceutical: Megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR- 100.2. Drugs R D 2007;8:403–406.
187. Morley JE, Logie P, Bensusan AD. The subjective effects of dagga: Including comparative studies with Britain and America. S Afr Med J 1973;47:1145–1149.
188. Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, Mahadevan A, et al. CB1 cannabinoid receptormediated modulation of food intake in mice. Br J Pharmacol 2005;145:293–300.
189. Gamber KM, Macarthur H, Westfall TC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 2005;49:646–652.
190. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005;280:25196–25201.
191. Piomelli D. A fatty gut feeling. Trends Endocrinol Metab 2013;24:332–341.
192. Gatta-Cherifi B, Matias I, Vallee M, Tabarin A, Marsicano G, Piazza PV, et al. Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity. Int J Obes (Lond) 2012;36:880–885.
193. Riggs PK, Vaida F, Rossi SS, Sorkin LS, Gouaux B, Grant I, Ellis RJ. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res 2012;1431:46–52.
194. Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydroncannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994;10:14–18.
195. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89–97.
196. Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndromeassociated anorexia. J Pain Symptom Manage 1997;14:7–14.
197. Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Cannabis-In-Cachexia-Study-Group. Comparison of orally administered cannabis extract and delta-9-testrahydrocannabinol in treating patients with cancer-related anorexiacachexia syndrome: A multicenter, phase III, randomized, double-blind, placebocontrolled clinical trail from the Cannabis-In-Cachexia-Study-Group.
198. Wilson MM, Philpot C, Morley JE. Anorexia of aging in long term care: Is dronabinol an effective appetite stimulant?—A pilot study. J Nutr Health Aging 2007;11:195–198.
199. Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: Results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 2011;22:2086–2093.
200. Morley JE. End-of-life care in the nursing home. J AmMed Dir Assoc 2011;12:77–83.
201. Diano S, Farr SA, Benoit SC, McNay EC, da Silva I, Horvath B, et al. Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci 2006;9:381–388.
202. Müller TD, Perez-Tilve D, Tong J, Pfluger PT, Tschöp MH. Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia. J Cachexia Sarcopenia Muscle 2010;1:159–167.
203. Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, Hosoda H, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003;9:774–778.
204. Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006;106:966–973.
205. DeBoer MD, Zhu XX, Levasseur P, Meguid MM, Suzuki S, Inui A, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 2007;148:3004–3012.
206. Chance WT, Dayal R, Friend LA, Thomas I, Sheriff S. Continuous intravenous infusion of ghrelin does not stimulate feeding in tumor-bearing rats. Nutr Cancer 2008;60:75–90.
207. Garcia JM, Cata JP, Dougherty PM, Smith RG. Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology 2008;149:455–460.
208. Yakabi K, Sadakane C, Noguchi M, Ohno S, Ro S, Chinen K, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology 2010;151:3773–3782.
209. Fujitsuka N, Asakawa A, Amitani H, Hattori T, Inui A. Efficacy of ghrelin in cancer cachexia: Clinical trials and a novel treatment by rikkunshito. Crit Rev Oncol 2012;17:277–284.
210. Ohno T, Yanai M, Ando H, Toyomasu Y, Ogawa A, Morita H, et al. Rikkunshito, a tranditional Japanese medicine, suppresses cisplatin-induced anorexia in humans. Clin Exp gastroenterol 2011;4:291–296.
211. Moschovi M, Trimis G, Vounatsou M, Katsibardi K, Margeli A, Dimitriadi F, et al. Serial plasma concentrations of PYY and ghrelin during chemotherapy in children with acute lymphoblastic leukemia. J Peditr Hematol Oncol 2008;30:733–737.
212. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J Clin Endocrniol Metab 2004;89:2832–2836.
213. Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, Tschöp M, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: A randomized, placebo-controlled, doubleblind, double-crossover study. Br J Cancer 2008;98:300–308.
214. Hiura Y, Takiguchi S, Yamamoto K, Takahashi T, Kurokawa YM, Yamasaki M, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study. Cancer 2012;118:4785–4794.
215. Yamamoto K, Takiguchi S, Miyata H, Adachi S, Hiura Y, Yamasaki M, et al. Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery 2010;148:31–38.
216. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancerrelated cachexia: A multicenter, randomized, double-blind, crossover, pilot study. Sup Care Cen 2013;21:129–137.
217. Morley JE, von Haehling S, Anker SD, Vellas B. From sarcopenia to frailty: A road less traveled. J Cachexia Sarcopenia 2014;5:5–8.
218. Morley JE. Weight loss in older persons: New therapeutic approaches. Curr Pharm Dis 2007;13:3637–3647.